The Syneos Health Podcast

Episode 010: Naming, Part 1 - The Pharma Company

January 08, 2018 Jeffrey Stewart, Kristen Spensieri, Joe Daley
The Syneos Health Podcast
Episode 010: Naming, Part 1 - The Pharma Company
Show Notes

What’s in a name? Quite a lot, actually, despite what Shakespeare says.

When it comes to a merger, this can be even more important.  With research showing that up to 80% of mergers fail – and one major reason being clashing corporate cultures during post-merger integration – choosing a name and brand that the entire organization can get behind is critical to success.

In this episode, listen to Kristen Spensieri of Syneos Health and Joe Daley of Syneos Health branding firm Addison Whitney discuss how the company is walking the talk – rebranding its own organization after the 2017 merger of INC Research and inVentiv Health, and how these principles can be applied to any company going through a rebrand.

Listen to Part 2 of our Naming series here.

See our full list of podcast episodes here.


The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.

The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. Syneos Health reserves the right to make alterations or deletions to the content at any time without notice to you.

Syneos Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.

The information, data and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any Syneos Health clients, customers or other contacts.